Anti-myeloma drug gets clinical trial nod from USFDA

The US health regulator has cleared Glenmark Pharma's investigational new drug application to initiate phase one study of GBR 1342, a humanised monoclonal antibody for treatment of multiple myeloma, the company said today.

This is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.

"GBR 1342 is designed to activate the patient's immune system by redirecting immune cells towards tumour tissue, which may lead to targeted destruction of tumours. It is based on Glenmark's proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform," Glenmak said in a BSE filing.

The first-in-human phase 1 study of GBR 1342 will enrol subjects with multiple myeloma who have exhausted available therapies.

"… our flagship biotechnology platform and antibody science are beginning to become a reality for patients now that we have a second oncology candidate entering clinical trials," Glenmark Pharma President and Chief Scientific Officer Kurt Stoeckli said. "While there is still significant development ahead, these steps signify that Glenmark's investment in discovery and development of biologics is rapidly progressing."

The study is being conducted in two parts.

GBR 1342 is also being considered for the treatment of other malignancies, the company said.

Source

ᐧ

Comments

Indian government outlines policies on drug pricing to favor poorer patients, and increase clinical trials

The Indian government is looking to review the existing drug price control measures in order to make medicines more affordable in the country, and at increasing the number of clinical trials taking place in the country, reports The Pharma Letter's India correspondent. In a parallel move, the Health Ministry is also preparing a framework for public private partnership to tackle the menace of non-communicable diseases in the country, In a move that could potentially result in affordable Medicare and health security moving to a larger section of the population, the government is considering a rash of policy measures in favor of poor patients. Talks are also on in government circles to abolish clinical trials on proven drugs that have been approved and marketed for at least two years in the European Union, United States, UK, Australia, Canada and Japan. A draft proposal in this regard has been prepared by the Health Ministry. If instituted, it would reduce the time taken to introduce n...

The polypill: Medicine's magic bullet

The capsule costs pennies, contains a simple cocktail of medicines, and halves the number of strokes and heart attacks. Doctors want to hand it out in the first mass medication for the middle-aged in Britain. So why are the big drug companies so uninterested? The magic bullet, containing five medicines in a single capsule, sharply reduced cholesterol and blood pressure levels and has the potential to "halve cardiovascular events in average middle-aged individuals", the researchers say. The finding is a major boost for a medication with huge potential against the worldwide epidemic of heart disease and stroke. Doctors say that, if further trials prove successful, all men aged over 50 and women aged over 60 should be offered the pill in what would be the first example of mass medication for the middle-aged in Britain. Yet no Western pharmaceutical company has shown interest in developing the so-called polypill because it does not promise big profits. It would sell for pennies b...

Registration of herbal trials in CTRI is not mandatory

A trial patient visited the site complaining breathlessness and tachycardia. The investigator advised hospitalization but as subject could not afford the expenses, he refused for admission. Is this an SAE because investigator advised hospitalization? G Praveen Kumar. If the patient was not hospitalized, it does not fall into SAE criteria of hospitalization. However, it appears from your mail that the PI felt that the event was serious enough to admit the subject for treatment. This makes it an “important medical event." As per ICH E2A such event also are considered serious. See the ICH E2A excerpt below: Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the defin...

My Clinical Trials Diary

Search This Blog